Tag: Bria-OTS™

October 16, 2019

BriaCell Announces Closing of Non-Brokered Private Placement of $568,444

BriaCell Therapeutics Corp. announces that it has closed its previously-announced non-brokered private placement.
October 7, 2019

BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer

BriaCell Therapeutics Corp. today announced that it has initiated dosing in a Phase I/IIa clinical study of its lead product...
October 2, 2019

BriaCell Therapeutics Corp. to Clarify Record Date

BriaCell Therapeutics Corp. announced on August 23, 2019 that it will hold a special meeting of shareholders on October 22,...
October 1, 2019

Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer. 
September 25, 2019

BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy’ Issue in Prestigious Journals

BriaCell Therapeutics announced the addition of immunology expert, Cara L. Haymaker, Ph.D., to its Scientific Advisory Board, effective immediately.
September 20, 2019

BriaCell Announces Private Placement of up to $600,000

BriaCell is pleased to announce a non-brokered private placement of up to approximately 8,571,428 common shares in the capital of...
September 19, 2019

BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®

BriaCell Therapeutics Corp. today announces that Dr. Williams, presented clinical updates of its Phase I/IIa clinical trial of Bria-IMT™.